Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
8(32%)
Results Posted
60%(6 trials)
Terminated
1(4%)

Phase Distribution

Ph phase_1
3
12%
Ph phase_4
4
16%
Ph phase_3
2
8%
Ph phase_2
14
56%
Ph not_applicable
1
4%

Phase Distribution

3

Early Stage

14

Mid Stage

6

Late Stage

Phase Distribution24 total trials
Phase 1Safety & dosage
3(12.5%)
Phase 2Efficacy & side effects
14(58.3%)
Phase 3Large-scale testing
2(8.3%)
Phase 4Post-market surveillance
4(16.7%)
N/ANon-phased studies
1(4.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

10 of 12 finished

Non-Completion Rate

16.7%

2 ended early

Currently Active

8

trials recruiting

Total Trials

25

all time

Status Distribution
Active(8)
Completed(10)
Terminated(2)
Other(5)

Detailed Status

Completed10
Recruiting7
unknown5
Active, not recruiting1
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
25
Active
8
Success Rate
90.9%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (12.5%)
Phase 214 (58.3%)
Phase 32 (8.3%)
Phase 44 (16.7%)
N/A1 (4.2%)

Trials by Status

completed1040%
active_not_recruiting14%
terminated14%
recruiting728%
unknown520%
withdrawn14%

Recent Activity

Clinical Trials (25)

Showing 20 of 25 trialsScroll for more
NCT06533748Phase 2

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Recruiting
NCT03286634Phase 2

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

Active Not Recruiting
NCT04043494Phase 3

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

Recruiting
NCT06387121Phase 2

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

Recruiting
NCT05660473Phase 2

Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Recruiting
NCT02303821Phase 1

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Completed
NCT03384654Phase 2

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Completed
NCT03643276Phase 3

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

Recruiting
NCT06279767Phase 1

Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma

Recruiting
NCT00199056Phase 4

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)

Completed
NCT00199069Phase 4

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)

Completed
NCT05506332Phase 1

Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
NCT01324336

Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets

Completed
NCT04228393Phase 2

The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China

Unknown
NCT01432145Phase 2

A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours

Completed
NCT02518750Phase 2

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Terminated
NCT03564704Phase 2

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL

Unknown
NCT03553238Phase 2

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL

Unknown
NCT00602134Not Applicable

Bioequivalence Study of 6-Mercaptopurine Under Fasting Conditions

Completed
NCT00514982Phase 2

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

Withdrawn

Drug Details

Intervention Type
DRUG
Total Trials
25